News
PODD
265.68
+0.93%
2.45
Weekly Report: what happened at PODD last week (1216-1220)?
Weekly Report · 4d ago
Materials, software stocks are best poised for H1 outperformance: Goldman Sachs
Seeking Alpha · 4d ago
DexCom, Insulet, Tandem benefit from Novo Nordisk CagriSema data
Seeking Alpha · 6d ago
Executive VP Of Insulet Sold 26% Of Their Shares
Simply Wall St · 6d ago
Here's Why Insulet (NASDAQ:PODD) Can Manage Its Debt Responsibly
Simply Wall St · 12/18 10:42
Weekly Report: what happened at PODD last week (1209-1213)?
Weekly Report · 12/16 09:05
Insulet Is Maintained at Overweight by JP Morgan
Dow Jones · 12/12 19:47
Insulet Price Target Raised to $330.00/Share From $280.00 by JP Morgan
Dow Jones · 12/12 19:47
JP Morgan Maintains Overweight on Insulet, Raises Price Target to $330
Benzinga · 12/12 19:37
RMD or PODD: Which Is the Better Value Stock Right Now?
NASDAQ · 12/12 16:40
J.P. Morgan Keeps Their Buy Rating on Insulet (PODD)
TipRanks · 12/12 12:06
Insulet’s Strong International Performance and Optimistic Type 2 Diabetes Market Outlook Drive Positive Analyst Rating
TipRanks · 12/12 10:26
Insulet Is Maintained at Buy by Citigroup
Dow Jones · 12/11 19:19
Insulet Price Target Raised to $310.00/Share From $283.00 by Citigroup
Dow Jones · 12/11 19:19
Citigroup Maintains Buy on Insulet, Raises Price Target to $310
Benzinga · 12/11 19:09
Decoding 11 Analyst Evaluations For Insulet
Benzinga · 12/11 19:01
Citi’s ‘SMID value creators’ stocks: GAP, CHWY, FHN, and more
Seeking Alpha · 12/11 17:47
Insulet Is Maintained at Overweight by Wells Fargo
Dow Jones · 12/11 15:19
Insulet Price Target Raised to $305.00/Share From $290.00 by Wells Fargo
Dow Jones · 12/11 15:19
Wells Fargo Maintains Overweight on Insulet, Raises Price Target to $305
Benzinga · 12/11 15:09
More
Webull provides a variety of real-time PODD stock news. You can receive the latest news about Insulet Corp through multiple platforms. This information may help you make smarter investment decisions.
About PODD
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, the Omnipod Insulin Management System, and Omnipod GO. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen's Neulasta. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. Omnipod 5 includes an AID algorithm embedded in the Pod.